Nuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management Services
Rhea-AI Summary
Nuwellis (Nasdaq: NUWE) has retained CORE IR for public relations, shareholder communications, and social media management, effective April 9, 2026. CORE IR will drive market awareness, convey Nuwellis' solutions and development plans, and manage digital communications to investors, partners, and key stakeholders.
The engagement aims to support Nuwellis' growth strategy and expand outreach across medical device and diagnostics markets through integrated multi-channel communications.
Positive
- None.
Negative
- None.
News Market Reaction – NUWE
On the day this news was published, NUWE declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
Pre-news, NUWE was down 4.42% while momentum peers were mixed: one mover up and two down. Broader device peers (e.g., BBLG, TIVC, VTAK, NAOV, VERO) also show a blend of gains and losses, suggesting company-specific factors rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 07 | Territory expansion | Positive | +3.7% | Created a dedicated South Texas commercial territory to deepen Aquadex adoption. |
| Mar 31 | Pediatric revenue update | Positive | +0.0% | Pediatric segment reached ~50% of U.S. revenue with expansion to 47 centers. |
| Mar 17 | Rendiatech acquisition | Positive | -8.5% | Closed acquisition adding automated continuous kidney function monitoring technology. |
| Mar 10 | Earnings results | Neutral | +0.8% | Reported Q4 2025 revenue growth and higher margins but full-year revenue decline and loss. |
| Mar 05 | Leadership appointment | Positive | -5.1% | Appointed Dr. Goldstein as Director of Clinical Strategy to bolster pediatric and cardiorenal focus. |
Recent news often focuses on strategic growth (territory expansion, pediatric traction, acquisition), with market reactions mixed and sometimes selling off on positive items like leadership additions and M&A.
Over the last few months, Nuwellis reported several growth-oriented developments. On Mar 5, it added a Director of Clinical Strategy, followed by Q4 and full-year 2025 results on Mar 10. The company then completed the Rendiatech acquisition on Mar 17, highlighted pediatric revenue momentum on Mar 31, and strengthened its U.S. footprint with a new South Texas territory on Apr 7. Today’s communications-focused engagement with CORE IR fits this broader push to support growth and market awareness.
Regulatory & Risk Context
An effective S-3 resale registration dated 2026-02-03 covers up to 4,279,325 warrant-related shares. Nuwellis would not receive proceeds from stockholder resales but could receive up to $28 million if all registered warrants are exercised for cash, implying potential future share issuance tied to those warrants.
Market Pulse Summary
This announcement centers on Nuwellis engaging CORE IR to strengthen investor relations, public relations, and digital outreach as it pursues growth in cardiorenal and pediatric markets. In recent months, the company expanded its U.S. footprint, completed the Rendiatech acquisition, and highlighted pediatric revenue momentum, while also disclosing going-concern risks and an effective resale registration of warrant shares. Investors may watch how improved communications affect capital access, adoption of Aquadex, and execution on these strategic initiatives.
AI-generated analysis. Not financial advice.
MINNEAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it has retained CORE IR, a leading investor relations, public relations, and strategic advisory firm, to assist the Company with public relations, shareholder communications, and social media management services.
Nuwellis Chairman and CEO John Erb commented, “We believe CORE IR’s integrated communications approach will enable us to more effectively articulate our value proposition to investors, partners, and key stakeholders. As we continue to expand our presence across the medical device and diagnostics markets, we see significant opportunities to drive long-term value. We look forward to working closely with CORE IR to communicate our growth strategy and highlight the opportunities ahead as we advance our trajectory.”
CORE IR will focus on expanding market awareness for Nuwellis, conveying Nuwellis’ solutions, business model, and development plans to target audiences, and providing public relations and digital communications services. CORE IR, a boutique Investor and Public Relations, Digital communications, and strategic advisory firm, specializes in leveraging effective investment, growth, and exposure strategies for small to mid-sized publicly traded and privately held companies through an integrated approach to relationship development and corporate communications.
“CORE IR is a great fit for Nuwellis as the breadth of our team’s experience and capabilities will serve the Company’s communications goals utilizing tailored strategies toward driving market awareness, expanding outreach, and engaging with relevant audiences. We look forward to a strong strategic partnership that facilitates consistent targeted communications through our multi-channel strategy,” added CORE IR’s Co-Founder and President Scott Gordon.
About CORE IR
CORE IR is comprised of senior market and practice leaders with expertise in institutional and retail investor relations, integrated public relations, corporate and digital communications, and capital markets advisory services. CORE IR provides proprietary integrated investor relations, public relations, and digital communications solutions that yield targeted exposure for small to mid-sized companies. For more information, please visit www.coreir.com.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
ir@nuwellis.com
Media Contact:
CORE PR
media@nuwellis.com
